Affiliation:
1. Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
2. Izmerov Research Institute of Occupational Health
3. City Polyclinic No. 8
4. Polyclinic No. 2 for Presidential Affairs of the Russian Federation
5. Idiklinik
Abstract
Introduction. Dietary nutrition is a physiological therapeutic and prophylactic approach for chronic pancreatitis during an exacerbation. Given the acute reaction of patients to various foods, specialized dietary products designed specifically for this pathology are of great importance. Aim. Evaluation of the clinical efficacy, safety and tolerability of the use of specialized therapeutic nutrition – jelly “Pancreatic” in chronic pancreatitis in the acute stage. Materials and methods. 20 patients of the main group with pancreatitis, along with standard therapy, received a dietary food product twice a day. The dynamics of pain, dyspeptic syndromes and intestinal dysfunction syndrome was studied; dynamics of the ultrasound picture of the pancreas; intestinal motility according to carbolene test; safety and tolerability of therapy by registering side effects and assessing the quality of life according to the SF-36 questionnaire, assessing well-being according to the visual analogue scale, and the organoleptic properties of the medicinal product. The comparison group consisted of 20 patients who received only standard pharmacotherapy. Results. The use of a dietary therapeutic food product is accompanied by a significant decrease in the frequency of nausea, belching, heaviness and flatulence in patients of the main group. The terms of relief or reduction in the intensity of symptoms of bitterness, nausea, heaviness in the abdomen, feelings of rapid satiety, flatulence were significantly lower in the main group (5–8 days compared to the control group (10–14 days). A significant normalization of GGT and CRP levels was established in the main group, while in the comparison group there was only a decrease in CRP. The ongoing complex therapy was accompanied by an improvement in the ultrasound picture of the pancreas, potentiation of the effects of pharmacotherapy and a significant improvement in the quality of life of patients. Conclusions. The conducted studies have shown high efficiency, good tolerability and safety of the therapeutic product “Pancreatic jelly” in the treatment of patients with chronic pancreatitis. Kissel “Pancreas” is recommended by the authors for active use in patients with pancreatitis as a therapeutic diet.
Reference26 articles.
1. Ivashkin V.T., Kriger A.G., Okhlobystin A.V., Anishchenko M.A., Kardasheva S.S., Alekseenko S.A. et al. Clinical guidelines for the diagnosis and treatment of chronic pancreatitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(2):99–156. (In Russ.) https://doi.org/10.22416/1382-4376-2022-32-2-99-156.
2. Sedova G.A., Fedorov I.G., Kosyura S.D., Shustova N.S., Ilchenko L.Yu., Storozhakov G.I. Modern ideas about the classification of chronic pancreatitis. Russian Journal of Evidence-Based Gastroenterology. 2013;(1):62–67. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=18909646.
3. Imaeva A.K., Mustafin T.I., Polovinkina S.R. Morbidity and mortality rates in acute pancreatitis as an indicator of the state of medical care at the regional level. Problems of Social Hygiene, Public Health and History of Medicine. 2020;28(6):1298–1303. (In Russ.) https://doi.org/10.32687/0869-866X-2020-28-6-1298-1303.
4. Ketwaroo G.A., Freedman S.D., Sheth S.G. Approach to patients with suspected chronic pancreatitis: a comprehensive review. Pancreas. 2015;44(2):173–180. https://doi.org/10.1097/MPA.0000000000000239.
5. Machicado J.D., Amann S.T., Anderson M.A., Abberbock J., Sherman S., Conwell D. et al. 2017. Quality of life in chronic pancreatitis is determined by constant pain, disability/unemployment, current smoking and associated co-morbidities. Am J Gastroenterol. 2017;112(4):633–642. https://doi.org/10.1038/ajg.2017.